bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S1 from Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer
Authors: Quintela-Fandino Miguel , Morales Serafín , Cortés-Salgado Alfonso , Manso Luis , Apala Juan V. , Muñoz Manuel , Gasol Cudos Ariadna , Salla Fortuny Joel , Gion María , Lopez-Alonso Antonio , Cortés Javier , Guerra Juan , Malón Diego , Caleiras Eduardo , Mulero Francisca , Mouron Silvana
Published: April 2023

Supplementary Figure 1: Microvessel confocal staining broken down by fluorescence channel
Supplementary Table 1 from Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer
Authors: Dagogo-Jack Ibiayi , Martinez Pablo , Yeap Beow Y. , Ambrogio Chiara , Ferris Lorin A. , Lydon Christine , Nguyen Tom , Jessop Nicholas A. , Iafrate A. John , Johnson Bruce E. , Lennerz Jochen K. , Shaw Alice T. , Awad Mark M.
Published: April 2023

Supplementary Table 1. Treatment Histories
Figure S5 from Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy
Authors: Yang Linlin , Shen Changxian , Pettit Cory J. , Li Tianyun , Hu Andrew J. , Miller Eric D. , Zhang Junran , Lin Steven H. , Williams Terence M.
Published: April 2023

AGS TP53 wildtype adenocarcinoma cells were not effectively radiosensitized by the combination of AZD1775 and radiation. DER= dose enhancement ratio.
Figure S4 from Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy
Authors: Yang Linlin , Shen Changxian , Pettit Cory J. , Li Tianyun , Hu Andrew J. , Miller Eric D. , Zhang Junran , Lin Steven H. , Williams Terence M.
Published: April 2023

Weight changes in nude mice compared to baseline (pre-therapy) weights over time (days). Note that radiation treatment was associated with decline in weight which recovered with time. Treatments occurred during Days 1-5 as described in the text.
Table S5 from PARP Inhibition Suppresses GR–MYCN–CDK5–RB1–E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer
Authors: Liu Bo , Li Likun , Yang Guang , Geng Chuandong , Luo Yong , Wu Wenhui , Manyam Ganiraju C. , Korentzelos Dimitrios , Park Sanghee , Tang Zhe , Wu Cheng , Dong Zhenyang , Sigouros Michael , Sboner Andrea , Beltran Himisha , Chen Yu , Corn Paul G. , Tetzlaff Michael T. , Troncoso Patricia , Broom Bradley , Thompson Timothy C.
Published: April 2023

Supplemental Table S5
Table S1 from PARP Inhibition Suppresses GR–MYCN–CDK5–RB1–E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer
Authors: Liu Bo , Li Likun , Yang Guang , Geng Chuandong , Luo Yong , Wu Wenhui , Manyam Ganiraju C. , Korentzelos Dimitrios , Park Sanghee , Tang Zhe , Wu Cheng , Dong Zhenyang , Sigouros Michael , Sboner Andrea , Beltran Himisha , Chen Yu , Corn Paul G. , Tetzlaff Michael T. , Troncoso Patricia , Broom Bradley , Thompson Timothy C.
Published: April 2023

Supplemental Table S1
Figure S1 from Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy
Authors: Yang Linlin , Shen Changxian , Pettit Cory J. , Li Tianyun , Hu Andrew J. , Miller Eric D. , Zhang Junran , Lin Steven H. , Williams Terence M.
Published: April 2023

CDK1 and genes from an AZD1775 responsiveness gene signature are up-regulated in ESCA, particularly squamous cell carcinoma. (A) Analysis of multiple esophageal cancer mRNA expression datasets (Su Esophagus 2 and Hu Esophagus) in Oncomine (http://oncomine.org/) confirms up-regulation of CDK1 in ESCA tumor versus normal tissues. Box plots were derived from gene expression data in Oncomine database, comparing expression of genes in normal tissue (left plot) and in ESCA tumor tissue (right plot). ESCC= Esophageal squamous cell carcinoma. Reporter #203213. (B) Analysis of multiple esophageal cancer mRNA expression datasets (Su Esophagus 2 and Hu Esophagus) in Oncomine (http://oncomine.org/) reveals increased expression of five genes potentially important as AZD1775 responsiveness predictors in human ESCA compared to normal tissue. Box plots were derived from Su Esophagus 2 (top panel), and Hu Esophagus (bottom panel) gene expression data in Oncomine database, ESCC= Esophageal squamous cell carcinoma.
Supplemental Tables from PARP Inhibition Suppresses GR–MYCN–CDK5–RB1–E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer
Authors: Liu Bo , Li Likun , Yang Guang , Geng Chuandong , Luo Yong , Wu Wenhui , Manyam Ganiraju C. , Korentzelos Dimitrios , Park Sanghee , Tang Zhe , Wu Cheng , Dong Zhenyang , Sigouros Michael , Sboner Andrea , Beltran Himisha , Chen Yu , Corn Paul G. , Tetzlaff Michael T. , Troncoso Patricia , Broom Bradley , Thompson Timothy C.
Published: April 2023

Supplemental Tables S2, S3, and S4
Supplementary table from Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Authors: Xie Changqing , Duffy Austin G. , Brar Gagandeep , Fioravanti Suzanne , Mabry-Hrones Donna , Walker Melissa , Bonilla Cecilia Monge , Wood Bradford J. , Citrin Deborah E. , Gil Ramirez Elizabeth M. , Escorcia Freddy E. , Redd Bernadette , Hernandez Jonathan M. , Davis Jeremy L. , Gasmi Billel , Kleiner David , Steinberg Seth M. , Jones Jennifer C. , Greten Tim F.
Published: April 2023

Supplemental table S1 and S2
Supplementary data from Anti-Folate Receptor Alpha–Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer
Authors: Cheung Anthony , Opzoomer James , Ilieva Kristina M. , Gazinska Patrycja , Hoffmann Ricarda M. , Mirza Hasan , Marlow Rebecca , Francesch-Domenech Erika , Fittall Matthew , Dominguez Rodriguez Diana , Clifford Angela , Badder Luned , Patel Nirmesh , Mele Silvia , Pellizzari Giulia , Bax Heather J. , Crescioli Silvia , Petranyi Gyula , Larcombe-Young Daniel , Josephs Debra H. , Canevari Silvana , Figini Mariangela , Pinder Sarah , Nestle Frank O. , Gillett Cheryl , Spicer James F. , Grigoriadis Anita , Tutt Andrew N.J. , Karagiannis Sophia N.
Published: April 2023

Supplementary Figure Legends, Materials and Methods
Supplemental Data from The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies
Authors: Stubbs Matthew C. , Burn Timothy C. , Sparks Richard , Maduskuie Thomas , Diamond Sharon , Rupar Mark , Wen Xiaoming , Volgina Alla , Zolotarjova Nina , Waeltz Paul , Favata Margaret , Jalluri Ravi , Liu Huiqing , Liu Xuesong Mike , Li Jun , Collins Robert , Falahatpisheh Nikoo , Polam Padmaja , DiMatteo Darlise , Feldman Patricia , Dostalik Valerie , Thekkat Pramod , Gardiner Christine , He Xin , Li Yanlong , Covington Maryanne , Wynn Richard , Ruggeri Bruce , Yeleswaram Swamy , Xue Chu-Biao , Yao Wenqing , Combs Andrew P. , Huber Reid , Hollis Gregory , Scherle Peggy , Liu Phillip C.C.
Published: April 2023

Supplemental Tables 1 & 2 Supplemental Figure Legends Supplemental Figures 1 - 5
Supplementary Data from U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors
Authors: Papadopoulos Kyriakos P. , Borazanci Erkut , Shaw Alice T. , Katayama Ryohei , Shimizu Yuki , Zhu Viola W. , Sun Thomas Yang , Wakelee Heather A. , Madison Russell , Schrock Alexa B. , Senaldi Giorgio , Nakao Naoki , Hanzawa Hiroyuki , Tachibana Masaya , Isoyama Takeshi , Nakamaru Kenji , Deng Chenhui , Li Meijing , Fan Frank , Zhao Qinying , Gao Yanfei , Seto Takashi , Jänne Pasi A. , Ou Sai-Hong Ignatius
Published: April 2023

Supplemental tables and figures
Supplementary Table S1-S4 from Skeletal Muscle Loss Is an Imaging Biomarker of Outcome after Definitive Chemoradiotherapy for Locally Advanced Cervical Cancer
Authors: Lee Jie , Chang Chih-Long , Lin Jhen-Bin , Wu Meng-Hao , Sun Fang-Ju , Jan Ya-Ting , Hsu Shih-Ming , Chen Yu-Jen
Published: April 2023

Supplementary Table S1 Patient and tumour characteristics according to muscle change (n = 245); Supplementary Table S2 Univariable Cox proportional hazards model for overall survival and cancer-specific survival (n = 245); Supplementary Table S3 Univariable and multivariable Cox proportional hazards model for overall survival and cancer-specific survival for patients with squamous cell carcinoma (n = 215); Supplementary Table S4 Acute toxicities by SATI and VATI groups (n = 245).
Supplementary Figure S3 from Skeletal Muscle Loss Is an Imaging Biomarker of Outcome after Definitive Chemoradiotherapy for Locally Advanced Cervical Cancer
Authors: Lee Jie , Chang Chih-Long , Lin Jhen-Bin , Wu Meng-Hao , Sun Fang-Ju , Jan Ya-Ting , Hsu Shih-Ming , Chen Yu-Jen
Published: April 2023

Kaplan-Meier curve demonstrating overall survival and cancer-specific survival for patients with squamous cell carcinoma (n = 215) according to (A, B) pre-treatment skeletal muscle index, (C, D) pre-treatment skeletal muscle density, (E, F) skeletal muscle change, (G, H) subcutaneous adipose tissue index, (I, J) visceral adipose tissue index groups. SMD, skeletal muscle density; SMI, skeletal muscle index; SATI, subcutaneous adipose tissue index; VATI visceral adipose tissue index.
Supplementary Figure S1 from Skeletal Muscle Loss Is an Imaging Biomarker of Outcome after Definitive Chemoradiotherapy for Locally Advanced Cervical Cancer
Authors: Lee Jie , Chang Chih-Long , Lin Jhen-Bin , Wu Meng-Hao , Sun Fang-Ju , Jan Ya-Ting , Hsu Shih-Ming , Chen Yu-Jen
Published: April 2023

The intraobserver reproducibility was tested by analysing data from 80 subjects randomly selected from this cohort. The measurements were repeated at two time points at least 1 month apart. ICC, intraclass correlation coefficients; CI, confidence interval.
Supplementary Data from Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma
Authors: Gordon Leo I. , Kaplan Jason B. , Popat Rakesh , Burris Howard A. , Ferrari Silvia , Madan Sumit , Patel Manish R. , Gritti Giuseppe , El-Sharkawi Dima , Chau Ian , Radford John A. , Pérez de Oteyza Jaime , Zinzani Pier Luigi , Iyer Swaminathan , Townsend William , Karmali Reem , Miao Harry , Proscurshim Igor , Wang Shining , Wu Yujun , Stumpo Kate , Shou Yaping , Carpio Cecilia , Bosch Francesc
Published: April 2023

SUPPLEMENTARY INFORMATION
Supplementary Table 6 from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
Authors: Rubio Carolina , Martínez-Fernández Mónica , Segovia Cristina , Lodewijk Iris , Suarez-Cabrera Cristian , Segrelles Carmen , López-Calderón Fernando , Munera-Maravilla Ester , Santos Mirentxu , Bernardini Alejandra , García-Escudero Ramón , Lorz Corina , Gómez-Rodriguez Maria José , de Velasco Guillermo , Otero Irene , Villacampa Felipe , Guerrero-Ramos Felix , Ruiz Sergio , de la Rosa Federico , Domínguez-Rodríguez Sara , Real Francisco X. , Malats Núria , Castellano Daniel , Dueñas Marta , Paramio Jesus M.
Published: April 2023

Supplementary Table 6: Spreadsheet of transcriptomic data
Supplementary Data from Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer
Authors: Tsujikawa Takahiro , Crocenzi Todd , Durham Jennifer N. , Sugar Elizabeth A. , Wu Annie A. , Onners Beth , Nauroth Julie M. , Anders Robert A. , Fertig Elana J. , Laheru Daniel A. , Reiss Kim , Vonderheide Robert H. , Ko Andrew H. , Tempero Margaret A. , Fisher George A. , Considine Michael , Danilova Ludmila , Brockstedt Dirk G. , Coussens Lisa M. , Jaffee Elizabeth M. , Le Dung T.
Published: April 2023

Supplementary Data
Supplementary Data from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
Authors: Rubio Carolina , Martínez-Fernández Mónica , Segovia Cristina , Lodewijk Iris , Suarez-Cabrera Cristian , Segrelles Carmen , López-Calderón Fernando , Munera-Maravilla Ester , Santos Mirentxu , Bernardini Alejandra , García-Escudero Ramón , Lorz Corina , Gómez-Rodriguez Maria José , de Velasco Guillermo , Otero Irene , Villacampa Felipe , Guerrero-Ramos Felix , Ruiz Sergio , de la Rosa Federico , Domínguez-Rodríguez Sara , Real Francisco X. , Malats Núria , Castellano Daniel , Dueñas Marta , Paramio Jesus M.
Published: April 2023

Includes Supplementary Figures 1-13; Supplementary Tables 1, 2, 3, 7 and 8; and Supplementary References
Supplementary Legend from Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection
Authors: Park Wungki , Chen Jiapeng , Chou Joanne F. , Varghese Anna M. , Yu Kenneth H. , Wong Winston , Capanu Marinela , Balachandran Vinod , McIntyre Caitlin A. , El Dika Imane , Khalil Danny N. , Harding James J. , Ghalehsari Nima , McKinnell Zoe , Chalasani Sree B. , Makarov Vladimir , Selenica Pier , Pei Xin , Lecomte Nicolas , Kelsen David P. , Abou-Alfa Ghassan K. , Robson Mark E. , Zhang Liying , Berger Michael F. , Schultz Nikolaus , Chan Timothy A. , Powell Simon N. , Reis-Filho Jorge S. , Iacobuzio-Donahue Christine A. , Riaz Nadeem , O'Reilly Eileen M.
Published: April 2023

Supplementary Data Legends
Supplement from Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis
Authors: Osipov Arsen , Lim Su Jin , Popovic Aleksandra , Azad Nilofer S. , Laheru Daniel A. , Zheng Lei , Jaffee Elizabeth M. , Wang Hao , Yarchoan Mark
Published: April 2023

Supplement: eTables 1-4, eFigures 1-7
Table S4 from Periostin and Epithelial–Mesenchymal Transition Score as Novel Prognostic Markers for Leiomyosarcoma, Myxofibrosarcoma, and Undifferentiated Pleomorphic Sarcoma
Authors: Piano Maria Assunta , Brunello Antonella , Cappellesso Rocco , Del Bianco Paola , Mattiolo Adriana , Fritegotto Chiara , Montini Barbara , Zamuner Carolina , Del Fiore Paolo , Rastrelli Marco , Sommariva Antonio , De Salvo Gian Luca , Montesco Maria Cristina , Rossi Carlo Riccardo , Zagonel Vittorina , Calabrò Maria Luisa
Published: April 2023

Characteristics of the 67 STS patients analyzed for circulating levels of periostin.
Figure S1 from Periostin and Epithelial–Mesenchymal Transition Score as Novel Prognostic Markers for Leiomyosarcoma, Myxofibrosarcoma, and Undifferentiated Pleomorphic Sarcoma
Authors: Piano Maria Assunta , Brunello Antonella , Cappellesso Rocco , Del Bianco Paola , Mattiolo Adriana , Fritegotto Chiara , Montini Barbara , Zamuner Carolina , Del Fiore Paolo , Rastrelli Marco , Sommariva Antonio , De Salvo Gian Luca , Montesco Maria Cristina , Rossi Carlo Riccardo , Zagonel Vittorina , Calabrò Maria Luisa
Published: April 2023

Flow diagram according to REMARK guidelines.
Supplementary Table Legends from A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma
Authors: Kandimalla Raju , Tomihara Hideo , Banwait Jasjit K. , Yamamura Kensuke , Singh Gagandeep , Baba Hideo , Goel Ajay
Published: April 2023

Supplementary Table Legends
Figure S6 from ΔNp63γ/SRC/Slug Signaling Axis Promotes Epithelial-to-Mesenchymal Transition in Squamous Cancers
Authors: Srivastava Kirtiman , Pickard Adam , Craig Stephanie G. , Quinn Gerard P. , Lambe Shauna M. , James Jacqueline A. , McDade Simon S. , McCance Dennis J.
Published: April 2023

Figure S6 shows (A) protein expressions of total p63 and β-actin in Scram siRNA (control), Slug siRNA mol-1 and mol-2 transfected E6/E7-HFK; (B) mRNA expressions of TP63, TP63α, TP63β and TP63γ in mol-2 transfected cells from (A). N=3 independent experiments. Data represented as mean {plus minus} s.e.m. and statistical significance calculated by Student's T-test.
Supplementary Figure Legends from Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma
Authors: Ishida Chiaki T. , Zhang Yiru , Bianchetti Elena , Shu Chang , Nguyen Trang T.T. , Kleiner Giulio , Sanchez-Quintero Maria J. , Quinzii Catarina M. , Westhoff Mike-Andrew , Karpel-Massler Georg , Prabhu Varun V. , Allen Joshua E. , Siegelin Markus D.
Published: April 2023

Supplementary Figure Legends
Figure S3 from ΔNp63γ/SRC/Slug Signaling Axis Promotes Epithelial-to-Mesenchymal Transition in Squamous Cancers
Authors: Srivastava Kirtiman , Pickard Adam , Craig Stephanie G. , Quinn Gerard P. , Lambe Shauna M. , James Jacqueline A. , McDade Simon S. , McCance Dennis J.
Published: April 2023

Figure S3 shows (A) immunofluorescence visualisation of E-cadherin (white arrows), Slug and nuclei (DAPI) in control (scram) and SNAI2 (mol-2) depleted E6/E7-HFK, respectively (B, C) Immunofluorescence staining of BrdU and nuclei (DAPI); and relative no. of BrdU positive cells per field of view on rafts established by E6/E7-HFK after transfection with scram (control) or Slug siRNA mol-2. Arrows indicate the invasive incidents. N=3 independent experiments. Data represented as mean {plus minus} s.e.m. and statistical significance was calculated by Student's t-test. NS=not significant.
Figure S2 from ΔNp63γ/SRC/Slug Signaling Axis Promotes Epithelial-to-Mesenchymal Transition in Squamous Cancers
Authors: Srivastava Kirtiman , Pickard Adam , Craig Stephanie G. , Quinn Gerard P. , Lambe Shauna M. , James Jacqueline A. , McDade Simon S. , McCance Dennis J.
Published: April 2023

Figure S2 shows (A) immunofluorescence detection of Slug, Snail and Twist proteins in normal epithelium and tumour areas from HPV+ve and HPV-ve OPSCC.(B) Protein expressions of Slug, Snail, Twist, N-cadherin, Fibronectin, ZEB-1, ZEB-2, GAPDH and β-actin in human foreskin fibroblast (HFF) and human foreskin keratinocytes (HFK) expressing either empty vector (pBabe) or HPV16 E6/E7 genes.
Supplementary Data from Immunotherapeutic Blockade of Macrophage Clever-1 Reactivates the CD8+ T-cell Response against Immunosuppressive Tumors
Authors: Viitala Miro , Virtakoivu Reetta , Tadayon Sina , Rannikko Jenna , Jalkanen Sirpa , Hollmén Maija
Published: April 2023

Supplementary figures
Table S1 from The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer
Authors: Kubota Yohei , Kawazoe Akihito , Sasaki Akinori , Mishima Saori , Sawada Kentaro , Nakamura Yoshiaki , Kotani Daisuke , Kuboki Yasutoshi , Taniguchi Hiroya , Kojima Takashi , Doi Toshihiko , Yoshino Takayuki , Ishii Genichiro , Kuwata Takeshi , Shitara Kohei
Published: April 2023

Clinical and molecular features of responders to anti-PD-1 therapy in each subtype.
Table S7 from The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas
Authors: Huang Manling , He Minghui , Guo Yu , Li Heping , Shen Shunli , Xie Yubin , Li Xiaoxing , Xiao Han , Fang Lujing , Li Dongming , Peng Baogang , Liang Lijian , Yu Jun , Kuang Ming , Xu Lixia , Peng Sui
Published: April 2023

Table S7 shows detailed information of candidate somatic mutations in the six HCC patients with WGS analysis.
Table S5 from The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas
Authors: Huang Manling , He Minghui , Guo Yu , Li Heping , Shen Shunli , Xie Yubin , Li Xiaoxing , Xiao Han , Fang Lujing , Li Dongming , Peng Baogang , Liang Lijian , Yu Jun , Kuang Ming , Xu Lixia , Peng Sui
Published: April 2023

Table S5 shows detailed information of structure variations in the six HCC patients with WGS analysis.
Table S1, Table S2, Table S4, Table S8, Table S10, Table S11 from The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas
Authors: Huang Manling , He Minghui , Guo Yu , Li Heping , Shen Shunli , Xie Yubin , Li Xiaoxing , Xiao Han , Fang Lujing , Li Dongming , Peng Baogang , Liang Lijian , Yu Jun , Kuang Ming , Xu Lixia , Peng Sui
Published: April 2023

Table S1 shows clinicopathologic information of 12 multifocal HCC patients. Table S2 shows PCR primers used for validation of HBV integration sites. Table S4 shows HBV integration analysis in HCC patients with WGS data. Table S8 shows P-value of pathways enrichment analysis in the small and large tumors of 12 multifocal HCC patients. Table S10 shows correlation between the number of rearrangements and immune activity. Table S11 shows detailed clinical data of eight patients with anti-PD-1 therapy.
Figures S1-S4 Table S1 from Molecular Imaging of Radiolabeled Bispecific T-Cell Engager 89Zr-AMG211 Targeting CEA-Positive Tumors
Authors: Waaijer Stijn J.H. , Warnders Frank J. , Stienen Sabine , Friedrich Matthias , Sternjak Alexander , Cheung H. Kam , van Scheltinga Anton G.T. Terwisscha , Schröder Carolien P. , de Vries Elisabeth G.E. , Lub-de Hooge Marjolijn N.
Published: April 2023

Supplementary Figures S1-S4 and Supplementary Table S1 including Supplementary Figure legend and Supplementary Table caption Figure S1. Flow chart of the drug substance (N-sucDf-AMG211) manufacturing process and drug product (89Zr-AMG211) formulation and filling process. Figure S2. Quality control of 89Zr AMG211. Representative size exclusion high performance liquid chromatography chromatogram of 89Zr AMG211 with 280 nm signal (top panel), radiochemical signal (middle panel) and the overlay (lower panel). Figure S3. Immunoreactivity of 89Zr AMG211. A) Representative competition assay using an effective N sucDf:AMG 211 ratio of 2:1. Curve fit with 95% confidence interval is visualized. B) Immunoreactivity towards CEA of different ratios N sucDf:AMG 211. Data are mean {plus minus} SD. Figure S4. Membrane binding and internalization of 89Zr AMG211 after CEA binding on LS174T cells (n = 3). Membrane bound and internalized 89Zr-AMG211 are expressed as percentage of initial cell associated activity. Data are mean {plus minus} SD. Figure S5. Expression of CEA on LS174T, BT474 and HL 60 cell lines (n = 3). Membrane expression is expressed as percentage of LS174T signal. Data are mean {plus minus} SD Table S1. GMP manufacturing of N sucDf AMG211 and 89Zr AMG211. Release criteria are fulfilled for batch 1, 2, and 3. In addition stability are shown for N sucDf AMG211 stored at 80{degree sign}C for 6 months, all quality criteria are still met.
Table S3 from Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine
Authors: Howard Thomas P. , Oberlick Elaine M. , Rees Matthew G. , Arnoff Taylor E. , Pham Minh-Tam , Brenan Lisa , DoCarmo Mariana , Hong Andrew L. , Kugener Guillaume , Chou Hsien-Chao , Drosos Yiannis , Mathias Kaeli M. , Ramos Pilar , Seashore-Ludlow Brinton , Giacomelli Andrew O. , Wang Xiaofeng , Freeman Burgess B. , Blankenship Kaley , Hoffmann Lauren , Tiv Hong L. , Gokhale Prafulla C. , Johannessen Cory M. , Stewart Elizabeth A. , Schreiber Stuart L. , Hahn William C. , Roberts Charles W.M.
Published: April 2023

Antibody sources and dilutions
Table S2 from Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine
Authors: Howard Thomas P. , Oberlick Elaine M. , Rees Matthew G. , Arnoff Taylor E. , Pham Minh-Tam , Brenan Lisa , DoCarmo Mariana , Hong Andrew L. , Kugener Guillaume , Chou Hsien-Chao , Drosos Yiannis , Mathias Kaeli M. , Ramos Pilar , Seashore-Ludlow Brinton , Giacomelli Andrew O. , Wang Xiaofeng , Freeman Burgess B. , Blankenship Kaley , Hoffmann Lauren , Tiv Hong L. , Gokhale Prafulla C. , Johannessen Cory M. , Stewart Elizabeth A. , Schreiber Stuart L. , Hahn William C. , Roberts Charles W.M.
Published: April 2023

Sources and catalog numbers of compounds
Table S7 from Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors
Authors: Shi Sailing , Gu Shengqing , Han Tong , Zhang Wubing , Huang Lei , Li Ziyi , Pan Deng , Fu Jingxin , Ge Jun , Brown Myles , Zhang Peng , Jiang Peng , Wucherpfennig Kai W. , Liu X. Shirley
Published: April 2023

Sup.Table.S7: Gene sets enriched in B16F10 tumors treated with anti-PD-L1 + swainsonine vs IgG +PBS. Pre-ranked gene set enrichment analysis (GSEA) was used to perform the analysis.
Figure S4 from Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929)
Authors: Da Silva Diane M. , Enserro Danielle M. , Mayadev Jyoti S. , Skeate Joseph G. , Matsuo Koji , Pham Huyen Q. , Lankes Heather A. , Moxley Katherine M. , Ghamande Sharad A. , Lin Yvonne G. , Schilder Russell J. , Birrer Michael J. , Kast W. Martin
Published: April 2023

Figure S4 shows the association of changes in immune biomarkers with overall survival
Table S4 from Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors
Authors: Shi Sailing , Gu Shengqing , Han Tong , Zhang Wubing , Huang Lei , Li Ziyi , Pan Deng , Fu Jingxin , Ge Jun , Brown Myles , Zhang Peng , Jiang Peng , Wucherpfennig Kai W. , Liu X. Shirley
Published: April 2023

Sup.Table.S4: Gene sets enriched in Man2a1-null B16F10 tumors vs control tumors treated with IgG isotype control. Pre-ranked gene set enrichment analysis (GSEA) was used to perform the analysis.
Table S1 from Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors
Authors: Shi Sailing , Gu Shengqing , Han Tong , Zhang Wubing , Huang Lei , Li Ziyi , Pan Deng , Fu Jingxin , Ge Jun , Brown Myles , Zhang Peng , Jiang Peng , Wucherpfennig Kai W. , Liu X. Shirley
Published: April 2023

Sup.Table.S1: N-glycan bio-synthesis gene list downloaded from KEGG (hsa00510).
Supplementary Data from A Gene Expression–based Model to Predict Metabolic Response After Two Courses of ABVD in Hodgkin Lymphoma Patients
Authors: Luminari Stefano , Donati Benedetta , Casali Massimiliano , Valli Riccardo , Santi Raffaella , Puccini Benedetta , Kovalchuk Sofya , Ruffini Alessia , Fama Angelo , Berti Valentina , Fragliasso Valentina , Zanelli Magda , Vergoni Federica , Versari Annibale , Rigacci Luigi , Merli Francesco , Ciarrocchi Alessia
Published: April 2023

Supplementary Figures and Tables
Figure S9 from Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors
Authors: Shi Sailing , Gu Shengqing , Han Tong , Zhang Wubing , Huang Lei , Li Ziyi , Pan Deng , Fu Jingxin , Ge Jun , Brown Myles , Zhang Peng , Jiang Peng , Wucherpfennig Kai W. , Liu X. Shirley
Published: April 2023

Sup.Fig.9: The effect of Man2a1 inhibition on the immune cell infiltration.
Figure S7 from Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors
Authors: Shi Sailing , Gu Shengqing , Han Tong , Zhang Wubing , Huang Lei , Li Ziyi , Pan Deng , Fu Jingxin , Ge Jun , Brown Myles , Zhang Peng , Jiang Peng , Wucherpfennig Kai W. , Liu X. Shirley
Published: April 2023

Sup.Fig.7: The relationship between the expression of down-regulated genes in Man2a1-knockout cells and ICB response or survival.
Supplementary Data from IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma
Authors: Chauvin Joe-Marc , Ka Mignane , Pagliano Ornella , Menna Carmine , Ding Quanquan , DeBlasio Richelle , Sanders Cindy , Hou Jiajie , Li Xian-Yang , Ferrone Soldano , Davar Diwakar , Kirkwood John M. , Johnston Robert J. , Korman Alan J. , Smyth Mark J. , Zarour Hassane M.
Published: April 2023

Supplemental Figure 1. TiNKs display lower TIGIT and CD226 expression, and lysis of CD155-expressing tumors than cNKs
Supplementary Data from IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma
Authors: Chauvin Joe-Marc , Ka Mignane , Pagliano Ornella , Menna Carmine , Ding Quanquan , DeBlasio Richelle , Sanders Cindy , Hou Jiajie , Li Xian-Yang , Ferrone Soldano , Davar Diwakar , Kirkwood John M. , Johnston Robert J. , Korman Alan J. , Smyth Mark J. , Zarour Hassane M.
Published: April 2023

Supplemental Figure 2. CD155 expression in melanoma cells inversely correlates with the TIGIT/CD226 expression ratio in TiNKs.
Figure S3 from Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors
Authors: Shi Sailing , Gu Shengqing , Han Tong , Zhang Wubing , Huang Lei , Li Ziyi , Pan Deng , Fu Jingxin , Ge Jun , Brown Myles , Zhang Peng , Jiang Peng , Wucherpfennig Kai W. , Liu X. Shirley
Published: April 2023

Sup.Fig.3: Gating strategy of T cell co-culture validation experiment.
Supplementary Data from IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma
Authors: Chauvin Joe-Marc , Ka Mignane , Pagliano Ornella , Menna Carmine , Ding Quanquan , DeBlasio Richelle , Sanders Cindy , Hou Jiajie , Li Xian-Yang , Ferrone Soldano , Davar Diwakar , Kirkwood John M. , Johnston Robert J. , Korman Alan J. , Smyth Mark J. , Zarour Hassane M.
Published: April 2023

Supplemental Figure 5. IL-15 and TIGIT blockade/deletion combine to suppress experimental lung metastasis of LWT1 melanoma.
Figure S2 from Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors
Authors: Shi Sailing , Gu Shengqing , Han Tong , Zhang Wubing , Huang Lei , Li Ziyi , Pan Deng , Fu Jingxin , Ge Jun , Brown Myles , Zhang Peng , Jiang Peng , Wucherpfennig Kai W. , Liu X. Shirley
Published: April 2023

Sup.Fig.2: Expression and T cell dysfunction score of MAN2A1.
Figure S10 from Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors
Authors: Shi Sailing , Gu Shengqing , Han Tong , Zhang Wubing , Huang Lei , Li Ziyi , Pan Deng , Fu Jingxin , Ge Jun , Brown Myles , Zhang Peng , Jiang Peng , Wucherpfennig Kai W. , Liu X. Shirley
Published: April 2023

Sup.Fig.10: H&E staining to evaluate immune-related adverse events of anti-PD-L1 and swainsonine.
Supplementary Data from A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer
Authors: Rodriguez Cristina P. , Wu Qian (Vicky) , Voutsinas Jenna , Fromm Jonathan R. , Jiang Xiuyun , Pillarisetty Venu G. , Lee Sylvia M. , Santana-Davila Rafael , Goulart Bernardo , Baik Christina S. , Chow Laura Q.M. , Eaton Keith , Martins Renato
Published: April 2023

Supplementary Material
Supplementary Data from A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer
Authors: Rodriguez Cristina P. , Wu Qian (Vicky) , Voutsinas Jenna , Fromm Jonathan R. , Jiang Xiuyun , Pillarisetty Venu G. , Lee Sylvia M. , Santana-Davila Rafael , Goulart Bernardo , Baik Christina S. , Chow Laura Q.M. , Eaton Keith , Martins Renato
Published: April 2023

Supplement Figure 1: Synergistic cytotoxic effect of pembrolizumab combined with vorinostat in HNSCC tissue slice culture. HNSCC slices (250 ï�­m) were cultured and treated with 20 ï�­g/ml of isotype control antibody IgG4 or pembrolizumab, with or without vorinostat (20 ï�­M, 100 ï�­M) for 6 days. Graph shows the percentage of cleaved-caspase-3+ cells. Unpaired student's tests, P-values are as follows: *p < 0.05, **P < 0.01, ***P< 0.001.
Supplementary Table 1 from Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors
Authors: Balmanoukian Ani S. , Infante Jeffrey R. , Aljumaily Raid , Naing Aung , Chintakuntlawar Ashish V. , Rizvi Naiyer A. , Ross Helen J. , Gordon Michael , Mallinder Philip R. , Elgeioushi Nairouz , González-García Ignacio , Standifer Nathan , Cann Jennifer , Durham Nicholas , Rahimian Shahram , Kumar Rakesh , Denlinger Crystal S.
Published: April 2023

Supplementary Table 1. Characteristics of patients with prolonged SD ({greater than or equal to}24 weeks)
Supplementary Figure 1 from Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis
Authors: Norsworthy Kelly J. , Mulkey Flora , Scott Emma C. , Ward Ashley F. , Przepiorka Donna , Charlab Rosane , Dorff Sarah E. , Deisseroth Albert , Kazandjian Dickran , Sridhara Rajeshwari , Beaver Julia A. , Farrell Ann T. , de Claro R. Angelo , Pazdur Richard
Published: April 2023

Supplementary Figure 1. Detailed flow diagram for ascertainment of DS cases.
Supplementary Figure 2 from Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma
Authors: Martini Jean-François , Plimack Elizabeth R. , Choueiri Toni K. , McDermott David F. , Puzanov Igor , Fishman Mayer N. , Cho Daniel C. , Vaishampayan Ulka , Rosbrook Bradley , Fernandez Kathrine C. , Tarazi Jamal C. , George Saby , Atkins Michael B.
Published: April 2023

Supplementary Figure 2
Supplementary Data from A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K-mutant Solid Tumors
Authors: Sullivan Ryan J. , Weber Jeffrey , Patel Sapna , Dummer Reinhard , Carlino Matteo S. , Tan Daniel S.W. , Lebbé Celeste , Siena Salvatore , Elez Elena , Wollenberg Lance , Pickard Michael D. , Sandor Victor , Ascierto Paolo A.
Published: April 2023

Supplementary data includes 3 supplemental tables
Supplementary Data from Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma
Authors: Pierceall William E. , Amatangelo Michael D. , Bahlis Nizar J. , Siegel David S. , Rahman Adeeb , Van Oekelen Oliver , Neri Paola , Young Mary , Chung Weiyuan , Serbina Natalya , Parekh Samir , Agarwal Amit , Thakurta Anjan
Published: April 2023

Supplementary Methods and Data
Supplementary Data from Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer
Authors: Richard François , Majjaj Samira , Venet David , Rothé Françoise , Pingitore Julien , Boeckx Bram , Marchio Caterina , Clatot Florian , Bertucci François , Mariani Odette , Galant Christine , Eynden Gert van den , Salgado Roberto , Biganzoli Elia , Lambrechts Diether , Vincent-Salomon Anne , Pruneri Giancarlo , Larsimont Denis , Sotiriou Christos , Desmedt Christine
Published: April 2023

Supplementary Data clean version
Supplementary Figure 5 from The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones
Authors: Poschke Isabel C. , Hassel Jessica C. , Rodriguez-Ehrenfried Aaron , Lindner Katharina A.M. , Heras-Murillo Ignacio , Appel Lena M. , Lehmann Johanna , Lövgren Tanja , Wickström Stina L. , Lauenstein Claudia , Roth Jasmin , König Anna-Katharina , Haanen John B.A.G. , van den Berg Joost , Kiessling Rolf , Bergmann Frank , Flossdorf Michael , Strobel Oliver , Offringa Rienk
Published: April 2023

Supplemental Figure 5: Intratumoral and intra-patient heterogeneity of the PDA and melanoma TIL TCR repertoire
Supplementary Figure 3 from The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones
Authors: Poschke Isabel C. , Hassel Jessica C. , Rodriguez-Ehrenfried Aaron , Lindner Katharina A.M. , Heras-Murillo Ignacio , Appel Lena M. , Lehmann Johanna , Lövgren Tanja , Wickström Stina L. , Lauenstein Claudia , Roth Jasmin , König Anna-Katharina , Haanen John B.A.G. , van den Berg Joost , Kiessling Rolf , Bergmann Frank , Flossdorf Michael , Strobel Oliver , Offringa Rienk
Published: April 2023

Supplemental Figure 3: Patterns of clonal shifts during early and late phase of in vitro TIL expansion
Figure S2 from A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma
Authors: Yang Zijian , LaRiviere Michael J. , Ko Jina , Till Jacob E. , Christensen Theresa , Yee Stephanie S. , Black Taylor A. , Tien Kyle , Lin Andrew , Shen Hanfei , Bhagwat Neha , Herman Daniel , Adallah Andrew , O'Hara Mark H. , Vollmer Charles M. , Katona Bryson W. , Stanger Ben Z. , Issadore David , Carpenter Erica L.
Published: April 2023

Figure S2. miRNA sequencing to discover miRNA biomarkers to discern PDAC from non-cancer. (A) Raw miRNA sequencing data from 6 healthy controls, 6 non-cancer disease controls, 5 M0 PDAC patients, and 12 M1 PDAC patients. (B) 8 potential miRNA candidates were selected using least absolute shrinkage and selection operator (LASSO) for cancer versus non-cancer, achieving AUC=1 within discovery cohort. (C) We selected 5 out of 8 miRNA candidates based on their abundance as detected by qPCR (Cq < 40) and show the average fold changes of these 5 miRNAs between patient groups. (D) We validated these miRNAs by calculating the correlation coefficient between their qPCR data and the miRNA sequencing data. The overall R2 = 0.6
Supplementary Data from Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expression
Authors: Walker Alison R. , Byrd John C. , Blachly James S. , Bhatnagar Bhavana , Mims Alice S. , Orwick Shelley , Lin Tara L. , Crosswell Howland E. , Zhang Danjie , Minden Mark D. , Munugalavadla Veerendra , Long Lauren , Liu Jinfeng , Pan Yang , Oellerich Thomas , Serve Hubert , Rao Arati V. , Blum William G.
Published: April 2023

Suppl Figures 1-3, Suppl Table 1 Supplemental Figure 1. Study schema. Supplemental Figure 2. Overall survival in patients treated with ENTO + 7+3. OS is censored on the date the patient was last known to be alive (if it was not known the patient had died by the end of study follow-up). Supplemental Figure 3. Heat map showing single patients (each column) by HOXA9 and MEIS1 categorization, cytogenetic or molecular risk and outcomes.
Supplementary Data from A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer
Authors: Corn Paul G. , Zhang Miao , Nogueras-Gonzalez Graciela M. , Xiao Lianchun , Zurita Amado J. , Subudhi Sumit K. , Tu Shi-Ming , Aparicio Ana M. , Coarfa Cristian , Rajapakshe Kimal , Huang Shixia , Navone Nora M. , Lin Sue-Hwa , Wang Guocan , Ramachandran Sumankalai , Titus Mark A. , Panaretakis Theocharis , Gallick Gary E. , Efstathiou Eleni , Troncoso Patricia , Logothetis Christopher
Published: April 2023

Additional Figures and Tables
Supplementary Figure 1 from Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer
Authors: Smyth Lillian M. , Tamura Kenji , Oliveira Mafalda , Ciruelos Eva M. , Mayer Ingrid A. , Sablin Marie-Paule , Biganzoli Laura , Ambrose Helen J. , Ashton Jack , Barnicle Alan , Cashell Des D. , Corcoran Claire , de Bruin Elza C. , Foxley Andrew , Hauser Joana , Lindemann Justin P.O. , Maudsley Rhiannon , McEwen Robert , Moschetta Michele , Pass Martin , Rowlands Vicky , Schiavon Gaia , Banerji Udai , Scaltriti Maurizio , Taylor Barry S. , Chandarlapaty Sarat , Baselga José , Hyman David M.
Published: April 2023

Supplementary Figure 1. Participant Flow Diagram
Figure S5 from Chloroquine Sensitizes GNAQ/11-mutated Melanoma to MEK1/2 Inhibition
Authors: Truong Amanda , Yoo Jae Hyuk , Scherzer Michael T. , Sanchez John Michael S. , Dale Kali J. , Kinsey Conan G. , Richards Jackson R. , Shin Donghan , Ghazi Phaedra C. , Onken Michael D. , Blumer Kendall J. , Odelberg Shannon J. , McMahon Martin
Published: April 2023

Bioluminescent images of hepatic tumors
Supplementary Figure 4 from PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer
Authors: Gray Katherine D. , McCloskey Jaclyn E. , Vedvyas Yogindra , Kalloo Olivia R. , Eshaky Steve El , Yang Yanping , Shevlin Enda , Zaman Marjan , Ullmann Timothy M. , Liang Heng , Stefanova Dessislava , Christos Paul J. , Scognamiglio Theresa , Tassler Andrew B. , Zarnegar Rasa , Fahey Thomas J. , Jin Moonsoo M. , Min Irene M.
Published: April 2023

A model for ICAM1-CAR T and anti-PD1 antibody activities in advanced thyroid cancers.
Figure S9 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia
Authors: Balachander Srividya B. , Criscione Steven W. , Byth Kate F. , Cidado Justin , Adam Ammar , Lewis Paula , Macintyre Terry , Wen Shenghua , Lawson Deborah , Burke Kathleen , Lubinski Tristan , Tyner Jeffrey W. , Kurtz Stephen E. , McWeeney Shannon K. , Varnes Jeffrey , Diebold R. Bruce , Gero Thomas , Ioannidis Stephanos , Hennessy Edward J. , McCoull William , Saeh Jamal C. , Tabatabai Areya , Tavana Omid , Su Nancy , Schuller Alwin , Garnett Mathew J. , Jaaks Patricia , Coker Elizabeth A. , Gregory Gareth P. , Newbold Andrea , Johnstone Ricky W. , Gangl Eric , Wild Martin , Zinda Michael , Secrist J. Paul , Davies Barry R. , Fawell Stephen E. , Gibbons Francis D.
Published: April 2023

Figure S9
Supplemental Figure SF-04 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2
Authors: Yang Richard K. , Kuznetsov Igor B. , Ranheim Erik A. , Wei Jun S. , Sindiri Sivasish , Gryder Berkley E. , Gangalapudi Vineela , Song Young K. , Patel Viharkumar , Hank Jacquelyn A. , Zuleger Cindy , Erbe Amy K. , Morris Zachary S. , Quale Renae , Kim KyungMann , Albertini Mark R. , Khan Javed , Sondel Paul M.
Published: April 2023

Hu14.18-IL2 Treatment Improves Direct Positive Correlations between Myeloid and Lymphoid Cells as indicated by ssGSEA Signatures
Figure S1 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia
Authors: Balachander Srividya B. , Criscione Steven W. , Byth Kate F. , Cidado Justin , Adam Ammar , Lewis Paula , Macintyre Terry , Wen Shenghua , Lawson Deborah , Burke Kathleen , Lubinski Tristan , Tyner Jeffrey W. , Kurtz Stephen E. , McWeeney Shannon K. , Varnes Jeffrey , Diebold R. Bruce , Gero Thomas , Ioannidis Stephanos , Hennessy Edward J. , McCoull William , Saeh Jamal C. , Tabatabai Areya , Tavana Omid , Su Nancy , Schuller Alwin , Garnett Mathew J. , Jaaks Patricia , Coker Elizabeth A. , Gregory Gareth P. , Newbold Andrea , Johnstone Ricky W. , Gangl Eric , Wild Martin , Zinda Michael , Secrist J. Paul , Davies Barry R. , Fawell Stephen E. , Gibbons Francis D.
Published: April 2023

Figure S1
Supplementary Table II from Low-Dose Hsp90 Inhibitor Selectively Radiosensitizes HNSCC and Pancreatic Xenografts
Authors: Mehta Ranjit K. , Pal Sanjima , Kondapi Koushik , Sitto Merna , Dewar Cuyler , Devasia Theresa , Schipper Matthew J. , Thomas Dafydd G. , Basrur Venkatesha , Pai Manjunath P. , Morishima Yoshihiro , Osawa Yoichi , Pratt William B. , Lawrence Theodore S. , Nyati Mukesh K.
Published: April 2023

List of proteins identified in TMT-LC/MS assay and list of enriched pathways
Supplementary Table I from Low-Dose Hsp90 Inhibitor Selectively Radiosensitizes HNSCC and Pancreatic Xenografts
Authors: Mehta Ranjit K. , Pal Sanjima , Kondapi Koushik , Sitto Merna , Dewar Cuyler , Devasia Theresa , Schipper Matthew J. , Thomas Dafydd G. , Basrur Venkatesha , Pai Manjunath P. , Morishima Yoshihiro , Osawa Yoichi , Pratt William B. , Lawrence Theodore S. , Nyati Mukesh K.
Published: April 2023

Supplementary Table I: list of clinical studies
Supplementary Data from A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors
Authors: Muller Mirte , Hummelink Karlijn , Hurkmans Daan P. , Niemeijer Anna-Larissa N. , Monkhorst Kim , Roder Joanna , Oliveira Carlos , Roder Heinrich , Aerts Joachim G. , Smit Egbert F.
Published: April 2023

Supplementary Data from A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors
Table S1 from AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer
Authors: McDaniel Nellie K. , Iida Mari , Nickel Kwangok P. , Longhurst Colin A. , Fischbach Samantha R. , Rodems Tamara S. , Kranjac Carlene A. , Bo Amber Y. , Luo Qianyun , Gallagher Meghan M. , Welke Noah B. , Mitchell Kaitlyn R. , Schulz Alison E. , Eckers Jaimee C. , Hu Rong , Salgia Ravi , Hong Seungpyo , Bruce Justine Y. , Kimple Randall J. , Wheeler Deric L.
Published: April 2023

Clinical characteristics of tumors
Figure S5 from AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer
Authors: McDaniel Nellie K. , Iida Mari , Nickel Kwangok P. , Longhurst Colin A. , Fischbach Samantha R. , Rodems Tamara S. , Kranjac Carlene A. , Bo Amber Y. , Luo Qianyun , Gallagher Meghan M. , Welke Noah B. , Mitchell Kaitlyn R. , Schulz Alison E. , Eckers Jaimee C. , Hu Rong , Salgia Ravi , Hong Seungpyo , Bruce Justine Y. , Kimple Randall J. , Wheeler Deric L.
Published: April 2023

siABL1+R428+Ctx in HN30-AXL WT
Figure S4 from AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer
Authors: McDaniel Nellie K. , Iida Mari , Nickel Kwangok P. , Longhurst Colin A. , Fischbach Samantha R. , Rodems Tamara S. , Kranjac Carlene A. , Bo Amber Y. , Luo Qianyun , Gallagher Meghan M. , Welke Noah B. , Mitchell Kaitlyn R. , Schulz Alison E. , Eckers Jaimee C. , Hu Rong , Salgia Ravi , Hong Seungpyo , Bruce Justine Y. , Kimple Randall J. , Wheeler Deric L.
Published: April 2023

ABL targeting in cetuximab-resistant clones
Supplement 8 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
Authors: Fenk Roland , Giagounidis Aristoteles , Goldschmidt Hartmut , Heinsch Michael , Rummel Mathias , Kroger Nicolaus , Boquoi Amelie , Lopez David , Gerrlich Celina , Baier Julia , Liesenjohann Svenja , Hauck Katarzyna , Savickaite Ingrida , Mai Elias K. , Aul Carlo , Strapatsas Judith , Dienst Ariane , Kondakci Mustafa , Haas Rainer , Kobbe Guido
Published: April 2023

Quality of life
Supplement 7 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
Authors: Fenk Roland , Giagounidis Aristoteles , Goldschmidt Hartmut , Heinsch Michael , Rummel Mathias , Kroger Nicolaus , Boquoi Amelie , Lopez David , Gerrlich Celina , Baier Julia , Liesenjohann Svenja , Hauck Katarzyna , Savickaite Ingrida , Mai Elias K. , Aul Carlo , Strapatsas Judith , Dienst Ariane , Kondakci Mustafa , Haas Rainer , Kobbe Guido
Published: April 2023

Second primary malignancies
Figure S1 from AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer
Authors: McDaniel Nellie K. , Iida Mari , Nickel Kwangok P. , Longhurst Colin A. , Fischbach Samantha R. , Rodems Tamara S. , Kranjac Carlene A. , Bo Amber Y. , Luo Qianyun , Gallagher Meghan M. , Welke Noah B. , Mitchell Kaitlyn R. , Schulz Alison E. , Eckers Jaimee C. , Hu Rong , Salgia Ravi , Hong Seungpyo , Bruce Justine Y. , Kimple Randall J. , Wheeler Deric L.
Published: April 2023

Ki67 staining in additional models
Supplementary Figure 2 from Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker Post Hoc Analysis of the VELOUR Trial
Authors: Van Cutsem Eric , Paccard Caroline , Chiron Marielle , Tabernero Josep
Published: April 2023

Supp Figure 2. PFS in patients with high VEGF-A or PlGF baseline plasma levels according to prior bevacizumab treatment. * adjusted for stratification.
Supplement 2 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
Authors: Fenk Roland , Giagounidis Aristoteles , Goldschmidt Hartmut , Heinsch Michael , Rummel Mathias , Kroger Nicolaus , Boquoi Amelie , Lopez David , Gerrlich Celina , Baier Julia , Liesenjohann Svenja , Hauck Katarzyna , Savickaite Ingrida , Mai Elias K. , Aul Carlo , Strapatsas Judith , Dienst Ariane , Kondakci Mustafa , Haas Rainer , Kobbe Guido
Published: April 2023

Discontinuations and dose reductions